Regen BioPharma Reports Significant Equity Issuances for Debt Conversion and Capital Raise

summarizeSummary

Regen BioPharma issued over 21 million common shares in January 2026, converting approximately $32,550 in convertible debt and raising $50,000 through a Regulation A offering.

check_boxKey Events

• Debt Conversion on January 15

  The company issued 5,000,000 common shares to satisfy $19,550 of convertible indebtedness (principal and interest).

• Additional Debt Conversion on January 29

  An additional 5,302,732 common shares were issued to satisfy $13,000 of convertible indebtedness (principal and interest).

• Regulation A Offering on January 30

  Regen BioPharma issued 11,111,111 common shares for $50,000 in cash, as part of a Tier 2 Regulation A Offering.

• Significant Dilution

  These transactions collectively resulted in the issuance of 21,413,843 new common shares, representing a substantial increase in the outstanding share count.

auto_awesomeAnalysis

This 8-K details several equity issuances in January 2026, resulting in substantial dilution for existing shareholders. The company converted approximately $32,550 of convertible debt into common shares and raised an additional $50,000 through a Tier 2 Regulation A offering. While these transactions provide some capital and reduce debt, the issuance of over 21 million shares represents a significant increase in the outstanding share count, impacting per-share value. This follows the Regulation A offering filed on January 8, 2026, indicating the company is actively seeking to raise capital.